Piracetam for fetal distress in labour

Summary: This review examined the effects of piracetam on delivery methods and newborn health during suspected fetal distress in labor. One study suggested piracetam might reduce the likelihood of a caesarean section, but there was no significant impact on neonatal health, leading to the conclusion that more evidence is needed.

Link: PubMed

Piracetam for acute ischaemic stroke

Summary: This study reviewed the use of piracetam in treating acute ischemic stroke and found no significant evidence to support its benefit, with a slight, but not statistically significant, trend towards increased early death which might be due to baseline differences in stroke severity. Also, there was no evidence of piracetam affecting functional outcomes, dependence, or mortality long-term.

Link: PubMed

Piracetam for reducing the incidence of painful sickle cell disease crises

Summary: This study reviewed three clinical trials to evaluate the effectiveness of piracetam for reducing painful sickle cell disease crises but found that the evidence was insufficient and of poor quality. Although some trials suggested potential benefits, the lack of reliable data and methodological issues prevented any clear conclusions, leading the authors to withhold recommendations for routine use of piracetam pending further research.

Link: PubMed

Piracetam in the treatment of cortical myoclonus

Summary: This paper reviews research and personal clinical experience on using piracetam to treat cortical myoclonus, showing that individualized high dosages (7-24g daily) can be very effective with minimal side effects. The authors’ experience with 12 patients suggests that up to 45g daily of piracetam can lead to significant long-term improvements, supporting its use as a primary treatment option for this condition.

Link: PubMed

Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis

Summary: This study investigates whether the nootropic drug piracetam improves memory in adults with cognitive impairments, comparing it to a placebo. The analysis of multiple clinical trials found no significant difference in memory enhancement between those taking piracetam and the placebo group, indicating that more research is needed to determine its true effectiveness.

Link: ScienceDirect

Physicochemical investigations of nootropic drug piracetam for enhanced solubilization as nano drug carrier under the influence of single and mixed micellar formulations: An optimized approach towards drug delivery

Summary: This study focused on developing micelles using nonionic surfactants Tween 80 and Triton-X 100 to enhance the solubilization and stability of piracetam. The results demonstrated that mixing these surfactants improves drug solubilization, showing that the process is spontaneous, entropically favorable, and stable due to the balanced hydrophilic and hydrophobic interactions.

Link: ScienceDirect

Effect of Piracetam and Iron Treatment on Heart Rate Variability in Patients With Breath-Holding Spell

Summary: This study investigated the effects of iron and piracetam on heart rate variability (HRV) in children with breath-holding spells using 24-hour Holter monitoring. Significant improvements in HRV parameters and a reduction in the number of breath-holding episodes were observed in patients treated with piracetam, suggesting its potential effectiveness.

Link: ScienceDirect

Efficacy and safety of compound porcine cerebroside and ganglioside injection (CPCGI) versus piracetam on cognition and functional outcomes for adults with traumatic brain injury: A study protocol for randomized controlled trial

Summary: This study aims to determine if a specific injection (CPCGI) can effectively improve cognitive and functional outcomes for patients with mild to moderate traumatic brain injury (TBI). It involves a large, controlled trial with 900 participants, comparing the effects of CPCGI to those of the drug piracetam over a three-month follow-up period.

Link: ScienceDirect

Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial

Summary: This study found that adding DHA to piracetam significantly reduced the frequency and severity of breath-holding spells in infants and preschool children compared to piracetam alone. Six months after treatment, only 16% of children treated with DHA and piracetam experienced breath-holding spells, compared to 50% with just piracetam.

Link: ScienceDirect

Piracetam mitigates nephrotoxicity induced by cisplatin via the AMPK-mediated PI3K/Akt and MAPK/JNK/ERK signaling pathways

Summary: This study investigated how Piracetam (PIR) may protect against kidney damage caused by the chemotherapy drug Cisplatin (CDDP). The researchers found that PIR improved kidney function, reduced tissue damage and inflammation, and balanced oxidative stress, making it a promising supplement to decrease CDDP-induced nephrotoxicity.

Link: ScienceDirect